Continuous-flow devices and percutaneous site infections: clinical outcomes.
about
Left ventricular assist device driveline infections: recent advances and future goalsTechnique for minimizing and treating driveline infections.Left ventricular assist devices-current state and perspectivesClinical outcomes after continuous-flow left ventricular assist device: a systematic reviewFirst series of left ventricular assist device exchanges to HeartMate 3.Pediatric ventricular assist devices: current challenges and future prospectsVAD infections: the lead, the graft and the pumpA review of infections in patients with left ventricular assist devices: prevention, diagnosis and management.Multidrug-Resistant Organism Infections in Patients with Left Ventricular Assist Devices.New Treatment for Percutaneous Sites in Patients with a Ventricular Assist Device: Nihon University Crystal Violet Method.Impact of adverse events on ventricular assist device outcomes.Hospital to Home with Mechanical Circulatory Support.INTERMACS and MedaMACS: how will they guide future therapy?State of the art of mechanical circulatory support.A simple device to secure ventricular assist device driveline and prevent exit-site infection.Minimally-invasive LVAD Implantation: State of the Art.HeartWare left ventricular assist device for the treatment of advanced heart failure.Challenges faced in long term ventricular assist device support.Complications, Risk Factors, and Staffing Patterns for Noncardiac Surgery in Patients with Left Ventricular Assist Devices.Surgical management of driveline infections in patients with left ventricular assist devices.Prototype Development of an Implantable Compliance Chamber for a Total Artificial Heart.Metabolic volume performs better than SUVmax in the detection of left ventricular assist device driveline infection.The value of fluorine-18 deoxyglucose positron emission tomography scans in patients with ventricular assist device specific infections†.Reduction of INCOR® driveline infection rate with silicone at the driveline exit site.Correlation between driveline features and driveline infection in left ventricular assist device selection.Topical Polymyxin-Trimethoprim Prophylaxis May Decrease the Incidence of Driveline Infections in Patients With Continuous-Flow Left Ventricular Assist Devices.Readmission due to driveline infection can be predicted by new score by using serum albumin and body mass index during long-term left ventricular assist device support.Infectious Complications of Mechanical Circulatory Support (MCS) Devices.Clinical outcomes associated with chronic antimicrobial suppression therapy in patients with continuous-flow left ventricular assist devices.Infectious complications of ventricular assist device use in children in the United States: Data from the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs).Left Ventricular Assist Device Infections: A Systematic Review.Left ventricle assist devices and driveline's infection incidence: a single-centre experience.Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography for improving diagnosis of infection in patients on CF-LVAD: longing for more 'insights'.Five-year results of patients supported by HeartMate II: outcomes and adverse events.The current state of left ventricular assist devices: challenges facing further development.Effect of far ultraviolet light emitted from an optical diffuser on methicillin-resistant Staphylococcus aureus in vitro
P2860
Q26770293-902B9B68-8B39-4C42-8C46-2CBD15BBE4C4Q26865692-37FEE877-18F2-4F9A-80DD-335D227605D8Q28074655-0AEAC8A2-C23A-4E48-931F-BBBFF5F16EF3Q30601099-9ECC74F7-24AB-469C-80B6-9B16AE4CE111Q33168444-5C73FA1E-9F42-45C1-B8E9-56E387B12488Q33707634-1BD685D6-FB80-4E53-A42B-CA40FE2E2E4EQ34498798-4330A80F-6831-4F5A-B02C-582845DCBAB5Q35183405-8AA9A10D-E61E-4C39-ADB7-A7A13D06B136Q36334445-B9F27D10-026C-4A59-94AD-24A3DDEEDF39Q37302779-153E5A64-FE05-42C8-89B3-255CE7701D66Q38073665-C77ED23C-1C31-4684-ACE0-3B4BB667DD3EQ38116755-18E64390-777C-4294-9B52-EE3A58EAF80AQ38123741-045F6F62-A081-4C84-8CB5-723971C39A88Q38210201-BF9D8B67-EF43-487A-98CA-064AAFF4F4BFQ38313206-8E2114AF-BA6E-467D-8896-8DE2B238A544Q38485093-C0B90501-5028-4465-8E87-AF4E7A6BFAD7Q38644478-B6199220-E847-4271-B11D-327D4CC492B8Q38845511-278941EB-4475-4AE9-89AF-5FDCCA4AFE4AQ39036332-D383A297-ED6A-478F-9136-CFFEF717A0C8Q39263857-B1C8BB62-07EB-491F-B080-F31A699E3B89Q39433926-00930B7E-C299-49C9-BA28-4AD556A51690Q40197711-7F1346DC-4E4D-42CC-81A6-98FA7CAAE1C6Q40283817-2A4F08D4-287D-415D-8ECE-C05C41E75FD7Q40517323-5CBE618E-CECC-4098-82BD-6AB97FCFE9EEQ40603345-20B52F15-7E59-4D9B-BE7E-56EFA4BE0FE6Q40706120-9B508031-FB61-438A-9E19-855B5BCADD9DQ41532622-F5FCA118-42FC-4D91-BF08-FB07B0B5D96BQ42246076-9E9475D0-098B-42FC-8601-B64FC014A3C0Q43611399-1850CF97-6D77-4FA2-98CB-5B3A73C3808DQ47377102-8EFB6B5D-2251-4150-8F75-250E215ADF79Q47388178-A5CADCEB-F29C-4746-B020-7A12F93EC62EQ47591294-7A81B6A7-6F59-4B44-A985-981A367FB9CCQ47602035-C733D337-8897-44A7-9F86-D4ABC9719857Q47622185-B750BC64-9CA5-4FAC-AE55-A43AC0962E08Q51662670-B5726A88-2AFA-4670-B04A-A5F4954F193FQ58791187-6C86F647-BA91-4041-BDC2-19D9E0482B30
P2860
Continuous-flow devices and percutaneous site infections: clinical outcomes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Continuous-flow devices and percutaneous site infections: clinical outcomes.
@en
Continuous-flow devices and percutaneous site infections: clinical outcomes.
@nl
type
label
Continuous-flow devices and percutaneous site infections: clinical outcomes.
@en
Continuous-flow devices and percutaneous site infections: clinical outcomes.
@nl
prefLabel
Continuous-flow devices and percutaneous site infections: clinical outcomes.
@en
Continuous-flow devices and percutaneous site infections: clinical outcomes.
@nl
P2093
P1476
Continuous-flow devices and percutaneous site infections: clinical outcomes
@en
P2093
Daniel J Goldstein
David Naftel
James Kirklin
Lavanya Bellumkonda
Salpy V Pamboukian
William Holman
P304
P356
10.1016/J.HEALUN.2012.05.004
P577
2012-07-04T00:00:00Z